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Abstract
Oncocytoma is a well-defined benign renal tumor, with classic gross and histologic features, including a tan or mahogany-col-
ored mass with central scar, microscopic nested architecture, bland cytology, and round, regular nuclei with prominent central 
nucleoli. As a result of variations in this classic appearance, difficulty in standardizing diagnostic criteria, and entities that mimic 
oncocytoma, such as eosinophilic variant chromophobe renal cell carcinoma and succinate dehydrogenase-deficient renal cell 
carcinoma, pathologic diagnosis remains a challenge. This review addresses the current state of pathologic diagnosis of oncocy-
toma, with emphasis on modern diagnostic markers, areas of controversy, and emerging techniques for less invasive diagnosis, 
including renal mass biopsy and advanced imaging.
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Introduction
Oncocytoma has been recognized for decades (1, 2) as a dis-
tinct subtype of benign renal tumor; however, despite evalu-
ation of numerous biomarkers performed over the years (3, 
4), pathologic diagnosis of oncocytoma and distinction from 
its mimics remain a challenge, even today (5). This review 
addresses the current state of pathologic diagnosis of onco-
cytoma, with emphasis on modern diagnostic markers, areas 
of controversy, and emerging techniques for less invasive di-
agnosis, including renal mass biopsy and specialized imaging 
techniques.
Gross Pathology
The characteristic gross appearance of oncocytoma includes 
a tan or mahogany brown cut surface (2, 6–8), generally sim-
ilar to normal renal parenchyma in color and in contrast 
to the golden yellow cut surface of clear cell renal cell car-
cinoma. Although a central scar is quite characteristic of 
oncocytoma (Figure 1A), it is not specific for oncocytoma 
and is not present in all tumors (2, 6–8). A central scar can 
also be found in chromophobe renal cell carcinoma, as well 
as other slow growing neoplasms, and substantial hyaliniza-
tion and fibrosis can also be present within clear cell renal cell 
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carcinoma. With the increasing identification of renal masses 
incidentally via imaging techniques, the size of oncocytoma 
tumors can also range from small solid nodules without cen-
tral scar to large masses that would otherwise be concerning 
for high-stage renal cell carcinoma.
Histopathology
The classic histologic appearance of renal oncocytoma in-
cludes nests and tubular structures lined by cells with eosino-
philic, granular cytoplasm (Figure 1B–D). Uncertainty in the 
diagnosis can arise when other patterns are present, such as 
a highly compact nested architecture, resulting in an almost 
entirely solid appearance, or when small papillary structures 
protrude into cystic spaces, raising concern of an eosino-
philic variant of papillary renal cell carcinoma. Oncocytomas 
typically contain edematous myxoid or hyalinized stroma, 
often resulting in at least some areas with nests and tubular 
structures dispersed in this stroma. Clear cytoplasm may also 
be focally present, typically in the area of the central scar.
Nuclei are characteristically round and regular; however, 
it is also established that oncocytomas can contain areas 
of “degenerative” cytologic atypia, resulting in patches of 
tumor cells with large nuclei, irregular nuclear contours, and 
smudged chromatin (8). Similar to other pseudomalignant 
features discussed elsewhere in this review, this finding is gen-
erally considered compatible with a benign diagnosis (8), es-
pecially if  other worrisome features such as increased mitotic 
activity are lacking. Mitotic activity is typically extremely rare 
in oncocytoma, and one of the most agreed-upon features is 
that finding a single mitotic figure with careful search may 
still be compatible with the diagnosis. However, more than 
(A) (B)
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Figure 1. The characteristic gross appearance of oncocytoma (A) varies depending on the size of the tumor, but often has a sim-
ilar color to normal renal parenchyma (mahogany brown) and characteristically, but not consistently, a central scar. Microscopic 
appearance typically includes nests dispersed in fibrous stroma (B) and can include tubular structures (C) or densely packed nests 
(D). Immunohistochemical staining for CK7 can be increased in the central scar area (E) but is typically limited to only scattered 
cells and small clusters of cells in other areas (F).
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one readily identifiable mitotic figure is quite worrisome or 
potentially incompatible with a diagnosis of oncocytoma (5).
An unusual pattern that is sometimes encountered in on-
cocytoma is the finding of areas with more scant cytoplasm, 
resulting in an appearance variably referred to as “small 
cell” oncocytoma, oncocytoma with pseudorosettes, or “on-
coblastic” cells (9). In general, such tumors appear to have 
overall immunohistochemical and molecular features similar 
to usual oncocytomas, at least regarding the most widely em-
ployed markers (9).
Immunohistochemistry
In considering the differential diagnosis of renal oncocytoma 
and other oncocytic neoplasms, the use of immunohistochem-
istry and special stains can be instructive. Oncocytomas gen-
erally show very minimal staining for cytokeratin 7 (CK7), 
typically limited to scattered individual cells or small clus-
ters of cells (5, 10), whereas a classic example of chromo-
phobe renal cell carcinoma (with pale-staining cytoplasm) is 
diffusely positive in a membranous distribution. In a recent 
study of urologic pathologists, CK7 was the most commonly 
utilized staining technique for diagnosing oncocytoma, al-
though a specific threshold of positive staining incompatible 
with oncocytoma was not well agreed upon (5). However, 
eosinophilic examples of chromophobe renal cell carcinoma 
may exhibit less extensive CK7 labeling (11), making selec-
tion of a positive staining threshold more challenging. In the 
survey of urologic pathologists, there was greatest acceptance 
for <5% of cells staining positively as supportive of onco-
cytoma, whereas comfort with an oncocytoma diagnosis de-
creased for greater extents of staining and entirely negative 
staining (5).
A confusing aspect of the existing published literature on 
CK7 staining in oncocytoma is that there is considerable 
variability between reported “positive” and “negative” results 
(3, 4), probably resulting from selection of cutoff  thresholds, 
in which some authors have interpreted minimal staining of 
<5% of cells as negative and others have interpreted this as 
positive. In addition, the central scar area of oncocytoma may 
exhibit increased staining for CK7 (Figure 1E) compared to 
the areas with usual morphology (Figure 1F), which could 
also potentially influence published results and lead to diag-
nostic challenges for anyone unfamiliar with this phenome-
non (12). The International Society of Urological Pathology 
(ISUP) consensus for best practices in immunohistochemis-
try recommends that immunohistochemistry be used in this 
context only for borderline cases (predominantly placing di-
agnostic emphasis on morphology and growth pattern) and 
notes CK7 as the most helpful marker in this scenario (11).
Other markers, such as kidney-specific cadherin and 
S100A1, are used by some laboratories, although these are 
less widely employed (5, 13–15). The use of colloidal iron 
staining (Hale or modified Mowry) is also often invoked in 
this setting as a histochemical technique. However, variation 
in staining techniques between laboratories can make inter-
pretation challenging, leading to variable use across practices. 
When working properly, oncocytomas will show negative or 
luminal staining, whereas chromophobe renal cell carcino-
mas will show diffuse, reticular cytoplasmic staining (16).
For distinction of oncocytoma and chromophobe renal 
cell carcinoma from other renal cell carcinoma subtypes, 
such as clear cell and papillary renal cell carcinoma variants 
with eosinophilic cytoplasm, markers such as KIT (CD117) 
and vimentin may be helpful, as both oncocytoma and 
chromophobe renal cell carcinoma share frequent membra-
nous positivity for KIT and negative staining for vimentin, 
in contrast to clear cell and papillary renal cell carcinoma, 
which characteristically have the opposite findings (negative 
KIT and often positive vimentin) (11, 17). Of note, vimentin 
staining is also commonly positive in the areas of central scar 
in oncocytoma, similar to the increased staining for CK7 in 
these areas, which may be a diagnostic pitfall, as it differs 
from the expected results (18).
Local Invasion
In addition to the pseudomalignant finding of degenerative 
type atypia, as discussed previously (Figure 2A), it is rela-
tively well known and accepted that oncocytomas can “in-
vade” or interdigitate with fat (Figure 2B–C), particularly 
perinephric fat, and to date this finding has not appeared to 
alter the benign clinical behavior of these tumors (6–8, 19). A 
potential explanation for this tendency to interdigitate with 
fat is that oncocytomas (as well as chromophobe renal cell 
carcinomas) tend to have a less continuous tumor pseudocap-
sule when compared to other renal cell carcinoma types, such 
as clear cell and papillary renal cell carcinoma (20). Although 
this is conceptually similar, a recent study of urologic pathol-
ogists revealed greater uncertainty for involvement of the 
renal sinus fat, in contrast to perinephric fat, the latter being 
more readily accepted as compatible with a benign diagno-
sis (5). Our interpretation is that involvement of fat in either 
of these locations remains compatible with an oncocytoma 
diagnosis. Notably, this invasion or interdigitation typically 
does not elicit any stromal reaction or response and has a 
scalloped or ballooning contour.
 It is also interesting that several reports have encoun-
tered vein or vein branch invasion in renal oncocytoma 
( Figure  2D), again noting that this does not appear to af-
fect the benign behavior of oncocytoma (8, 21, 22). In renal 
cell carcinomas, extension into a vein or vein branch would 
warrant a pT3a pathologic stage category; however, vascu-
lar involvement by benign renal tumors, especially angio-
myolipoma and rarely other entities, has also been reported 
(23–25). These studies suggest that vascular involvement is 
not inherently indicative of malignancy alone and may occur 
particularly in renal tumors, through poorly understood 
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mechanisms. Vascular extension by benign tumors of other 
organs has also been described, most notably intravascular 
leiomyomatosis of the gynecologic tract (26). This makes the 
distinction of oncocytoma from renal cell carcinoma even 
more critical, as it involves discriminating a benign neoplasm 
with vascular extension from a high-stage renal cell carci-
noma, the latter being potentially eligible for enrollment in 
clinical trials for adjuvant treatment.
Genetics
Many advanced genetic studies of renal oncocytoma have 
been employed, largely in the research setting. However, tra-
ditional cytogenetics (karyotyping), comparative genomic 
hybridization (CGH), and fluorescence in situ hybridization 
(FISH) are sometimes utilized in clinical diagnostic work (5). 
Based on karyotype data, oncocytomas have been generally 
found to exhibit either a diploid karyotype, loss of chro-
mosome 1, loss of Y, or rearrangement of 11q13, including 
t(5;11)(q35;q13) (2). As it is the locus of the CCND1 gene 
(cyclin D1), it has been subsequently found that many of 
these likely represent rearrangements involving CCND1, and 
emerging data suggest that oncocytomas harboring such rear-
rangements may represent a distinctive tumor subset (27, 28).
Sukov et al. found that more than half  of oncocytomas 
with cyclin D1 immunohistochemical labeling had CCND1 
rearrangement by FISH, compared to only a single tumor 
with rearrangement by FISH but without cyclin D1 stain-
ing (27). Interestingly, most of the cyclin D1-positive 
oncocytomas were solitary, whereas there was a considerable 
rate of multifocality in the cyclin D1-negative patients (27). 
In another study, Joshi et al. proposed dividing oncocytomas 
into type 1 and type 2 tumors, the former characterized by a 
diploid karyotype and CCND1 rearrangement. Conversely, 
the type 2 group was associated with recurrent loss of chro-
mosome 1, X, Y, 14, or 21, arguing for more genetic overlap 
with chromophobe renal cell carcinoma in this subgroup and 
leading the authors to speculate that this group might rep-
resent a precursor to eosinophilic variant chromophobe renal 
cell carcinoma (28).
Both oncocytoma and chromophobe renal cell carcinoma 
are noted to have mutations in mitochondrial genes (28–30). 
However, chromophobe renal cell carcinoma characteristi-
cally exhibits multiple chromosomal losses, including com-
monly chromosomes Y, 1, 2, 6, 10, 13, 17, and 21 (29) and 
lesser rates of chromosomes 3, 5, 8, 9, 11, and 18 (30). Other 
authors have also found chromosomal gains (31). TP53 ap-
pears to be among the more commonly mutated genes in 
chromophobe renal cell carcinoma, followed by PTEN (30). 
Additionally, TERT gene promoter rearrangements have 
also been found to occur in a subset of chromophobe tumors 
(30). Although some authors have found eosinophilic vari-
ant chromophobe renal cell carcinoma to harbor a similar 
pattern of chromosomal loss to usual chromophobe tumors 
when defined strictly (32), other studies have found a lower 
rate of chromosomal abnormality in eosinophilic variant 
chromophobe tumors, further blurring the distinction be-
tween these two diagnostic entities (30).
(A) (B)
(D)(C)
Figure 2. Pseudomalignant features in oncocytoma can include degenerative-type atypia (A), intermingling of the tumor with 
fat (B–C), and vascular invasion or large vein invasion (D). Despite that these would confer a high stage to renal cell carcinoma, 
they are currently thought to have no impact on the benign behavior of oncocytoma.
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In some unique contexts, such as the Birt–Hogg–Dubé 
syndrome and renal oncocytosis (multiple oncocytic renal tu-
mors without findings of Birt–Hogg–Dubé syndrome) (33), 
tumors are often referred to as oncocytomas, chromophobe 
renal cell carcinomas, or hybrid oncocytoma–chromophobe 
tumors (HOCT) (34, 35). However, it remains incompletely 
understood whether these should be regarded as true onco-
cytomas and chromophobe tumors, or whether they should 
be considered pathologically and genetically distinct entities 
(36). Some authors have found that intermediate stages of 
chromosomal alterations can be found in this setting, sug-
gesting a stepwise progression from oncocytoma to chro-
mophobe renal cell carcinoma (33), whereas others have 
found neoplasms of oncocytosis to have some differences in 
chromosomal aberration patterns, compared to usual onco-
cytoma and chromophobe renal cell carcinoma, suggesting 
that these neoplasms are molecularly distinct (34). “Hybrid 
tumors” have also been reported sporadically (without the 
context of a multiple tumor syndrome), which appear to be 
associated with multiple chromosomal gains and losses (37).
Overall, knowledge of these typical chromosomal altera-
tions can be helpful in assessing challenging cases, including 
resection specimens, whether by conventional karyotyping, 
FISH, and CGH, or through other methods. In general, a 
diploid karyotype or loss of chromosome 1 in the appropri-
ate morphologic and immunohistochemical context can be 
considered supportive of an oncocytoma diagnosis, whereas 
other losses or other alterations not typical of oncocytoma 
might be used to favor a borderline diagnosis or classification 
as chromophobe renal cell carcinoma.
Renal Mass Biopsy
Core needle biopsies are increasingly used in the diagnosis 
of renal masses (Figure 3). Because 20–45% of small renal 
masses are ultimately found to be benign, active surveillance 
is an option for many patients (38, 39). The diagnostic accu-
racy of renal mass biopsy remains somewhat controversial, 
however. Individual groups have reported up to 80% diag-
nostic rate from renal mass biopsy, with the ability to provide 
subtype and nuclear grade in the majority of diagnostic bi-
opsies (40). 
Unfortunately, oncocytic lesions can be especially trouble-
some in renal mass biopsy, as interpreting only a limited sam-
pling of tumor may not be representative of the entire lesion. 
A meta-analysis of 205 oncocytic renal mass biopsies from 
2017 showed that the positive predictive value for a diagnosis 
of oncocytoma on renal mass biopsy was 67% with signifi-
cant heterogeneity and wide confidence interval, indicating 
that the diagnostic accuracy varies greatly between studies 
and, by extrapolation, between pathologists (41).
For renal mass biopsies of oncocytic neoplasms, there is a 
split among urologic pathologists as to whether it is prefera-
ble to issue an outright diagnosis of oncocytoma (when fea-
tures are typical in the biopsy sample) or to use more general 
terminology, such as “oncocytic neoplasm,” with comment 
(A) (B)
(D)(C)
Figure 3. Core needle biopsy of oncocytoma (A) demonstrates tubular structures lined by homogeneous eosinophilic cells with 
round, regular nuclei (B). The typical immunohistochemical staining pattern includes rare CK7-positive cells (C) and negative 
vimentin staining (D), the latter highlighting only the vasculature.
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that the features are compatible with oncocytoma (5). In the 
context that morphologic and immunohistochemical features 
are largely compatible with oncocytoma, yet in which there 
are minor equivocal features, such as variation in cell size 
or slight nuclear irregularity, it is also reasonable to utilize 
a borderline diagnostic category expressing uncertainty be-
tween oncocytoma and eosinophilic variant chromophobe 
renal cell carcinoma. In this setting, immunohistochemical 
staining may also be helpful. Although CK7 staining may not 
be beyond the expected level of oncocytoma, findings such as 
negative vimentin staining and positive KIT staining gener-
ally argue against other considerations, such as papillary or 
clear cell renal cell carcinoma with eosinophilic cells. Since 
chromophobe renal cell carcinoma, especially the eosino-
philic variant, is also generally regarded as a less aggressive 
tumor subtype, this can facilitate appropriate management in 
patients who are candidates for nonsurgical treatment (42). 
Conversely, if  nuclear or cytologic features are inconsistent 
with oncocytoma (non-degenerative atypia, nuclear mem-
brane irregularity, or perinuclear clearing), a diagnosis of eo-
sinophilic variant of chromophobe renal cell carcinoma may 
be favored.
Differential Diagnosis
Although oncocytic or eosinophilic areas can be seen in al-
most any renal neoplasm, there are a few entities which may 
closely resemble oncocytoma throughout the majority of the 
mass. Broadly, these are neoplasms with a solid or nested pat-
tern of growth and abundant eosinophilic cytoplasm. A few 
entities most likely to mimic oncocytoma are discussed below 
(Table 1).
Chromophobe renal cell carcinoma
Chromophobe renal cell carcinoma has the most mor-
phologic overlap with oncocytoma, particularly the eo-
sinophilic variant, and presents the main diagnostic 
conundrum. Indeed, since there are “gray zone” tumors 
that are difficult to classify as either oncocytoma or eo-
sinophilic variant of  chromophobe renal cell carcinoma 
(8), it is tempting to consider these diagnoses as a spec-
trum. Grossly, chromophobe renal cell carcinoma can also 
mimic oncocytoma, presenting as a well-circumscribed 
tan-brown mass, sometimes also containing a central 
scar. The classic histologic appearance of  chromophobe 
renal cell carcinoma includes solid or trabecular architec-
ture, some nuclear atypia, well-preserved chromatin and 
wrinkled (“raisinoid”) nuclei, or more subtly occasional 
notched nuclei. Cells are often so voluminous, with low 
nuclear–cytoplasmic ratio, that some appear to have no 
nucleus at all due to sectioning artifact. Some tumors have 
substantial trabecular growth such that one could trace a 
long, imaginary line through tumor cells without crossing 
stroma or vasculature, something that would be impossible 
with the intricate vascular network of  clear cell renal cell 
carcinoma or the nested architecture of  oncocytoma.
The degree of  nuclear membrane irregularity typically 
seen in chromophobe renal cell carcinoma is generally 
considered not compatible with the diagnosis of  onco-
cytoma (Figure 4A); however, in the study of  109 onco-
cytomas by Trpkov et al., focal chromophobe renal cell 
carcinoma-like cytology (<5% of  the neoplasm) did not 
alter the benign behavior of  any tumor in the study (8). 
Other hallmark features include perinuclear cytoplasmic 
clearing or “halo,” as well as binucleate cells and well-de-
fined cellular borders (the so-called vegetable cells) (43). 
As noted previously, although the ISUP recommendation 
is to rely predominantly on morphologic features for the 
differential diagnosis of  oncocytoma versus chromophobe 
renal cell carcinoma, immunohistochemistry for CK7 
can be useful in this setting, with more extensive labeling 
found in chromophobe renal cell carcinoma compared to 
the scattered individual cell pattern of  oncocytoma. We 
would generally consider contiguous patches of  positive 
CK7 labeling to argue against a diagnosis of  oncocytoma, 
although a specific threshold of  positive staining is not 
entirely agreed upon (5, 11, 12).
Hybrid oncocytoma–chromophobe tumor
The term “hybrid oncocytoma–chromophobe tumor” 
is relatively widely used in the literature for tumors with 
mixed features of  oncocytoma and chromophobe renal cell 
carcinoma. However, the definitive criteria for use of  this 
terminology remain somewhat poorly defined. In general, 
this refers to a neoplasm with some areas resembling on-
cocytoma and other areas resembling chromophobe renal 
cell carcinoma, in our usage typically forming a mosaic 
or mixed pattern. However, reported usage of  this term is 
variable, with some pathologists using it in the context of 
an apparent syndrome (multiple tumors), others using it 
only with mosaic or mixed morphology, and some others 
using it for any tumor with borderline features between 
oncocytoma and chromophobe renal cell carcinoma (5). 
Therefore, reported series of  renal mass biopsies in which 
some oncocytomas were upgraded to malignancy as “hy-
brid tumor” at surgical resection may be confounded by the 
remaining uncertainty as to what exactly constitutes a true 
“hybrid.” Some of  these may represent oncocytomas with 
borderline atypical features (8). At the ISUP Vancouver 
Classification of  Renal Neoplasia, there was not agreement 
as to whether “hybrid tumor” represents a unique entity, 
and therefore it remained, for lack of  consensus, consid-
ered as a subdivision of  chromophobe renal cell carcinoma 
(36), an approach also employed by the 2016 World Health 
Organization Classification (29).
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Table 1: Typical characteristics of oncocytoma and differential diagnostic considerations
Central scar
Papillary 
structures
Classic 
architectural 
pattern
Nuclei CK7 KIT Vimentin AMACR SDHB
Mela-
nocytic 
markers
Oncocytoma Classic but 
only subset
No or rare 
abortive
Nested, 
tubules
Round, regular 
with central 
nucleoli
Rare single 
cells and clus-
ters of cells
+ - (except 
central scar)
Variable but usu-
ally lesser intensity
+ -
Chromophobe 
RCC, eosinophilic
Sometimes No Solid, 
trabecular
Irregular, 
wrinkled 
(variable)
Variable to 
diffuse
+ - Variable but usu-
ally lesser intensity
+ -
Chromophobe 
RCC, classic
Sometimes No Solid, 
trabecular
Irregular, 
wrinkled
+ (diffuse) + - Variable but usu-
ally lesser intensity
+ -
SDH-deficient 
RCC
Unknown Usually no 
(rare vari-
ant cases)
Solid Round, regular - - (mast 
cells 
present)
- (usually) Variable but usu-
ally lesser intensity
- (loss) -
Papillary RCC, 
eosinophilic
Usually not Yes Papillary Usually round 
to oval, regular
Variable, 
sometimes 
minimal
- + Strong + -
Tubulocystic 
RCC
Usually not No Cystic Hobnail-
ing, usually 
round with 
macronucleoli
Variable - + Strong + -
Epithelioid AML Usually not No Solid Round, oval, 
prominent 
nucleoli, vari-
able mild to 
marked atypia, 
multinucleate 
forms
- - + No data + +
Note: Most common findings are reported. RCC, renal cell carcinoma; SDH, succinate dehydrogenase; AML, angiomyolipoma; AMACR, alpha-methyl-acyl-coA racemase; 
SDHB, succinate dehydrogenase B.
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Figure 4. Mimics of oncocytoma include eosinophilic variant chromophobe renal cell carcinoma (A), in which distinction from 
oncocytoma is challenging, but is favored by perinuclear clearing (“halo”), nuclear wrinkling and irregularity, and substantial 
trabecular growth pattern. Succinate dehydrogenase-deficient renal cell carcinoma (B) is a more recently recognized entity that 
may closely mimic oncocytoma due to bland, uniform cytology; however, clues to this diagnosis include diffuse growth pattern 
(rather than tubular or nested formation) and cytoplasmic inclusions of flocculent material (sometimes referred to as vacuoles), 
likely representing large abnormal mitochondria. Papillary renal cell carcinoma with oncocytic features (C) can also mimic 
oncocytoma; however, this diagnosis should be suspected in the presence of substantive papillary formation (D) or positivity 
for vimentin (E). Labeling for alpha-methyl-acyl-coA racemase (AMACR) is typically very strong and diffuse in all patterns of 
papillary renal cell carcinoma (F).
Renal oncocytoma
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Succinate dehydrogenase-deficient renal cell 
carcinoma
Succinate dehydrogenase (SDH)-deficient renal cell carci-
noma is a recently recognized and rare entity that can also 
mimic oncocytoma due to its composition by cytologically 
bland, monomorphic, eosinophilic cells (Figure 4B) (44–47). 
These tumors are associated with an autosomal dominant 
mutation in subunits of the SDH complex genes, a compo-
nent of the mitochondrial complex II. As part of the hered-
itary paraganglioma-pheochromocytoma syndrome, these 
tumors can be associated with other neoplasms, including 
gastrointestinal stromal tumor (GIST), paraganglioma, and 
pituitary adenoma (44–47).
Morphologically, SDH-deficient renal cell carcinoma is 
composed of sheets and nests of cells with clear to eosino-
philic cytoplasm and low-grade nuclear features. Although 
the tumor cells may form glandular structures or cysts, they 
are often arranged in a rather diffuse pattern, which may 
leave doubt regarding the renal tubular nature (47). The 
classic histologic finding for these tumors is the presence 
of eosinophilic, flocculent inclusions within the cytoplasm 
(Figure 4B). Although sometimes referred to as cytoplasmic 
vacuoles, these structures likely represent enlarged, abnormal 
mitochondria (47, 48).
Since all normal cells should have a functioning Krebs 
cycle, and since detection of mitochondrial proteins is readily 
achieved in eosinophilic renal cell tumors (due to high mito-
chondrial density), the diagnosis of SDH-deficient renal cell 
carcinoma can be readily confirmed with abnormal negative 
immunohistochemical staining for the SDHB protein. Al-
though rare renal tumors with mutations in other subunits 
of the SDH complex (49, 50) or negative SDHA staining (47) 
have been reported, in general it appears that defects in any 
of the subunits destabilize the enzyme complex, resulting in 
abnormal negative SDHB staining regardless of which gene 
harbors the mutation (51), making SDHB a useful screening 
immunohistochemical marker. Other immunohistochemical 
clues to this diagnosis include a complete lack of CK7 reac-
tivity, contrasting to the rare scattered cells of oncocytoma, a 
paucity of positivity for epithelial markers overall, and nega-
tive staining for KIT (but often many intratumoral mast cells 
highlighted by KIT staining) (47).
Papillary renal cell carcinoma with eosinophilic cells
Oncocytomas do not show papillary growth, with the excep-
tion of rare abortive tufts protruding into dilated tubules or 
microcysts (6–8); therefore, the identification of any areas 
with substantive papillary features will usually exclude the 
diagnosis of oncocytoma. Classification as an eosinophilic 
form of papillary renal cell carcinoma (Figure 4C–D) can 
be additionally supported by the presence of foamy macro-
phages, or by immunohistochemical staining results, such as 
positive vimentin (Figure 4E), very diffuse and strong labeling 
for alpha-methyl-acyl-coA racemase (AMACR, Figure 4F), 
and negative staining for KIT. Although positive CK7 is gen-
erally considered a feature of papillary renal cell carcinoma, 
this is less true in eosinophilic examples, and therefore limited 
CK7 staining may not be helpful in excluding the possibil-
ity of papillary renal cell carcinoma (52). Oncocytomas may 
have degenerative atypia, but frank atypia without the typical 
smudged chromatin pattern would also make this diagnosis 
unlikely. Clear cytoplasm may occasionally be seen in areas 
near the central scar of an oncocytoma, but predominantly 
clear cell features are not consistent with the diagnosis.
Epithelioid angiomyolipoma
Epithelioid angiomyolipoma (or perivascular epithelioid 
cell neoplasm/PEComa) (53–55) can mimic oncocytoma as 
a solid or nested neoplasm with abundant eosinophilic cy-
toplasms. Although the trifecta of epithelioid eosinophilic 
cells, thick-walled blood vessels, and fat is diagnostic of the 
entity, occasionally the other components do not make up a 
significant proportion of the tumor (56–59). In the epithe-
lioid variant of angiomyolipoma, nuclear atypia is usually 
quite marked, excluding a diagnosis of oncocytoma and 
raising consideration of a high-grade renal cell carcinoma. 
Large multinucleated cells are often present, sometimes con-
taining central eosinophilic cytoplasm, a ring of nuclei, and 
peripheral clearing, somewhat reminiscent of Touton-type 
giant cells, as well as other multinucleate forms that have 
been variably described as “spider cells,” ameboid, ganglion-
like, or strap-like (56–59). A rare variant of angiomyolipoma 
reported by Martignoni et al., however, was noted to more 
closely resemble oncocytoma (60). If  there is any question 
as to the exact nature of the epithelioid cells, a PAX8 immu-
nohistochemical stain can be used to identify renal epithelial 
cell lineage. Epithelioid angiomyolipoma will exhibit neg-
ative staining, whereas oncocytomas and other neoplasms 
of renal cell origin typically show diffuse nuclear positivity. 
Conversely, epithelioid angiomyolipoma will exhibit at least 
focal labeling for melanocytic markers, including HMB-45, 
melan-A, and MiTF, as well as usually diffuse labeling for 
cathepsin K (61).
Tubulocystic renal cell carcinoma
Most cases of tubulocystic renal cell carcinoma would not be 
confused with oncocytoma due to their characteristic mor-
phology of tubular and cystic spaces, lined by cells with eos-
inophilic cytoplasm and hobnail-shaped cells with prominent 
nucleoli. However, a recent study focused on examples of cystic 
oncocytoma, which may be a source of confusion, and com-
pared them to tubulocystic renal cell carcinoma (62). Skenderi 
et al. found that tubulocystic renal cell carcinomas were more 
frequently positive for vimentin, AMACR, CD10, and CK7, 
and had a higher Ki67 proliferative index than cystic oncocy-
toma (62). Cystic oncocytomas were typically positive for KIT, 
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in contrast to negative staining in tubulocystic renal cell car-
cinomas. Morphologically, islands of cells within the fibrous 
stroma and solid nests were also regarded as a helpful clue fa-
voring oncocytoma over tubulocystic renal cell carcinoma (62).
Imaging
Oncocytomas are usually asymptomatic and are often dis-
covered incidentally on cross-sectional imaging performed 
for other indications. Much research is under way to deter-
mine a way to distinguish oncocytoma from renal cell carci-
noma by imaging and, therefore, to potentially avoid surgery 
for a benign tumor (63–65). Although frequently associated 
with a central scar and hypervascularity, these findings are 
not sufficient to make a definitive diagnosis of oncocytoma 
(66). With the increased use of cross-sectional imaging, renal 
masses are being identified much more frequently with con-
comitant overtreatment of benign neoplasms, such as on-
cocytoma (67). Currently, there are no precise radiologic 
criteria for oncocytoma.
Recent work has shown promising results for the use of 
technetium-99m (99mTc)-sestamibi single-photon emis-
sion computed tomography/x-ray computed tomography 
(SPECT/CT) to differentiate oncocytomas and hybrid onco-
cytic/chromophobe tumors from other renal cell carcinomas 
(68). In an updated series of cases, this new modality showed 
an overall sensitivity of 87.5% and a specificity of 95.2% (69).
Conclusion
Oncocytomas are a common, benign renal neoplasm that 
may be detected incidentally. It is critical to identify them as 
benign and to recognize the potential pitfalls that may cause 
doubt about the diagnosis—renal fat involvement, vascular 
invasion, and degenerative atypia. With the increasing use of 
renal mass biopsy, it is also important to know the limitations 
of the technique and use appropriate criteria before diagnos-
ing an oncocytoma in a limited biopsy specimen.
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